Preferred Label : Valganciclovir;
MeSH definition : A ganciclovir prodrug and antiviral agent that is used to treat CYTOMEGALOVIRUS RETINITIS
in patients with AIDS, and for the prevention of CYTOMEGALOVIRUS INFECTIONS in organ
transplant recipients who have received an organ from a CMV-positive donor.;
MeSH synonym : Ganciclovir L-valyl Ester; Ganciclovir L valyl Ester;
MeSH CAS label : L-Valine, 2-((2-amino-3,6-dihydro-6-oxo-9H-purin-9-yl)methoxy)-3-hydroxypropyl ester;
MeSH Related Number : 4P3T9QF9NZ;
UNII : GCU97FKN3R;
Origin ID : D000077562;
UMLS CUI : C0909381;
ATC code(s)
Allowable qualifiers
Pharmacological action(s)
Record concept(s)
See also inter- (CISMeF)
Semantic type(s)
Validated automatic mappings to BTNT
A ganciclovir prodrug and antiviral agent that is used to treat CYTOMEGALOVIRUS RETINITIS
in patients with AIDS, and for the prevention of CYTOMEGALOVIRUS INFECTIONS in organ
transplant recipients who have received an organ from a CMV-positive donor.
https://ansm.sante.fr/informations-de-securite/rovalcyte-r-50-mg-ml-poudre-pour-solution-buvable-valganciclovir-modification-des-graduations-de-la-nouvelle-seringue-pour-administration-orale-de-mg-a-ml
2021
false
false
false
France
French
pharmacovigilance note
Valganciclovir
---
http://www.has-sante.fr/portail/jcms/c_2761853/fr/rovalcyte
2017
false
France
French
evaluation of the transparency committee
infant, newborn
infant
child
adolescent
treatment outcome
insurance, health, reimbursement
valganciclovir hydrochloride
administration, oral
valganciclovir
antiviral agents
kidney transplantation
cytomegalovirus infections
ganciclovir
Valganciclovir
---
https://www.has-sante.fr/portail/jcms/c_2882052/fr/rovalcyte
2017
true
France
French
evaluation of the transparency committee
infant, newborn
infant
child
adolescent
treatment outcome
insurance, health, reimbursement
adult
cytomegalovirus retinitis
valganciclovir hydrochloride
administration, oral
valganciclovir
antiviral agents
organ transplantation
cytomegalovirus infections
ganciclovir
Valganciclovir
---
http://www.pharmactuel.com/index.php/pharmactuel/article/view/1071
2016
false
false
false
Canada
French
journal article
chemoprevention
antiviral agents
critical appraisal or critical reading
treatment outcome
risk factors
opportunistic infections
multicenter studies as topic
neutropenia
antiviral agents
valganciclovir
continuity of patient care
cytomegalovirus infections
polymerase chain reaction
DNA, viral
hematopoietic stem cell transplantation
allografts
cytomegalovirus infections
ganciclovir
ganciclovir
ganciclovir
Valganciclovir
Valganciclovir
---
http://www.has-sante.fr/portail/jcms/c_1254070/rovalcyte
http://www.has-sante.fr/portail/jcms/c_1716259/fr/rovalcyte
http://www.has-sante.fr/portail/jcms/c_1716258/fr/rovalcyte18122013avisct12980
2013
France
French
evaluation of the transparency committee
valganciclovir hydrochloride
administration, oral
valganciclovir
antiviral agents
kidney transplantation
cytomegalovirus infections
ganciclovir
Valganciclovir
---
http://www.pharmactuel.com/index.php/pharmactuel/article/view/819
2011
false
false
false
Canada
journal article
Treatment Efficacy
evaluation studies as topic
treatment outcome
cytomegalovirus
kidney transplantation
critique
risk
Valganciclovir
---